Research programme: prophylactic vaccines - Merck
Latest Information Update: 28 Aug 2025
At a glance
- Originator Merck Sharp & Dohme Corp.
- Developer Merck Sharp & Dohme Corp.; Symvivo
- Class DNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for preclinical development in Unspecified(Prevention) in Canada (PO)
- 01 Jul 2021 Preclinical trials in Unspecified (Prevention) in Canada (PO) (Symvivo Corporation pipeline, July 2021)
- 05 Jan 2021 Merck Sharp and Dohme Corp. receives an option to in-license bacTRL™ gene delivery platform technology from Symvivo